Tetraphase Pharmaceuticals to Participate at Upcoming Investor Conferences
August 27 2018 - 6:00AM
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical
company focused on developing and commercializing novel antibiotics
to treat life-threatening multidrug-resistant (MDR) infections,
today announced that company management will participate at the
following upcoming investor conferences:
- B. Riley FBR Healthcare Conference and Panel Discussion:
“Vaccines and antibiotics can't be developed for intractable
infectious diseases” (Track 1: The Great Debates: Controversies in
Biotech) on Tuesday, September 4, 2018 at 1:55 p.m. Eastern Time at
the New York Marriott East Side Hotel in New York City.
- H. C. Wainwright 20th Annual Global Investment Conference on
Wednesday, September 5, 2018 at 12:30 p.m. Eastern Time at the St.
Regis Hotel in New York City.
A live audio webcast of the H. C. Wainwright
presentation will be available on the company’s website at
http://ir.tphase.com/events.cfm. The archived presentation will be
available for 30 days.
About Tetraphase Pharmaceuticals,
Inc.Tetraphase is a biopharmaceutical company using its
proprietary chemistry technology to create novel antibiotics for
serious and life-threatening bacterial infections, including those
caused by many of the multidrug-resistant bacteria highlighted as
urgent public health threats by the World Health Organization and
Centers for Disease Control and Prevention. The Company has created
more than 3,000 novel tetracycline compounds using its proprietary
technology platform. Tetraphase's pipeline includes three
antibiotic clinical candidates: eravacycline, TP-271 and TP-6076.
Eravacycline has completed phase 3 clinical testing and is under
review for potential approval in cIAI by the U.S. Food and Drug
Administration, with a Prescription Drug User Fee Act date of
August 28, 2018 and has received a positive opinion from the
Committee for Medicinal Products for Human Use of the European
Medicines Agency. TP-271 and TP-6076 are in phase 1 clinical
trials. Please visit www.tphase.com for more company
information.
Media and Investor Contact:Tetraphase
PharmaceuticalsJennifer Viera617-600-7040jviera@tphase.com
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Jul 2024 to Jul 2024
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Jul 2023 to Jul 2024